home





























 

















 





















hrsa

participating institutions:
Johns Hopkins University AIDS Service, New York State DOH AIDS Institute, The CORE Center, Cook County Hospital



ADULT AND ADOLESCENT ART

last updated: April 23, 2001


COMPLETE GUIDELINES:


html pdf selected tables panel members


RELATED INFORMATION:


newslinks


Considerations for Discontinuing Therapy

As recommendations evolve, patients who have begun highly active antiretroviral therapy at CD4 T cell counts >350/mm3 may wish to discontinue treatment. There are no clinical data addressing whether or not this should be done or can be accomplished safely. Potential benefits include reduction of toxicities, drug-drug interactions, selection of resistant variants, and improvement in the quality of life. Potential risks include rebound in viral replication and renewed immunologic deterioration. If the patient and physician agree to discontinue therapy the patient should be closely monitored.






Copyright © 2001-2002. The National AIDS Education and Training Centers Program on behalf of its AETC National Resource Center. All rights reserved.

Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained in this site because no single reference or service can take the place of medical training, education, and experience. Consumers are cautioned that this site is not intended to provide medical advice about any specific medical condition they may have or treatment they may need, and they are encouraged to call or see their physician or other health care provider promptly with any health related questions they may have.